Lyell Immunopharma Inc., a clinical-stage company focused on CAR T-cell therapies, has announced new management appointments to strengthen its clinical and commercial capabilities. Mark J. Bachleda, PharmD, MBA, has been appointed as an independent member of the Board of Directors. Additionally, David Shook, MD, has been named Chief Medical Officer, Mark Meltz, JD, as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA, as Senior Vice-President of Medical Affairs. These changes come as Lyell advances its programs for LYL314, targeting aggressive large B-cell lymphoma.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。